On October 8, 2026 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, reported that two abstracts featuring GLIX1 will be presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day, taking place November 12-15 in Philadelphia, Pennsylvania.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will highlight preclinical research evaluating GLIX1 across multiple glioblastoma models, as well as the design of the ongoing Phase 1/2a clinical trial evaluating GLIX1 in patients with recurrent or progressive high-grade glioma and other solid tumors.

Presentation Details:

Title: GLIX1, a TET2 activator targeting DNA damage response: potent anti-tumor activity across multiple glioblastoma models; orthotopic CDX models and a subcutaneous TMZ-resistant PDX model
Presenter: Dr. Adam Robertson, Ph.D., Chief Scientific Officer, Hemispherian AS
Abstract code: EXTH-31
Format: Poster presentation
Date/time: Friday, November 13, 2026, 7:30-9:30 p.m. EST
Location: Pennsylvania Convention Center, Exhibit Halls D and E

Title: Phase 1/2a study of GLIX1, a novel first-in-class oral TET2 activator, for the treatment of recurrent or progressive high-grade glioma
Presenter: Ditte Primdahl, MD, Northwestern University Feinberg School of Medicine
Abstract code: CTNI-25
Format: Poster presentation
Date/time: Friday, November 13, 2026, 7:30-9:30 p.m. EST
Location: Pennsylvania Convention Center, Exhibit Halls D and E

(Press release, BioLineRx, OCT 8, 2026, View Source [SID1234673288])